Oxidative stress can trigger inflammation and atherosclerosis. Nowadays, the management of atherothrombotic syndromes has gained much attention to defeat atherosclerosis. However, the cost and potential side effects of the existing thrombolytic drugs limiting their use. This study aims to develop a new protocol to screen and say possible action mechanism of a thrombolytic agent trialed and evaluated an anti-atherothrombosis effect of the methanol extract of Dysophyllla auricularia (MDA). For this, hydrogen peroxide (H 2 O 2 )-induced hemolysis (HL) test was conducted to check its antioxidant capacity, while clotlysis (CL) for anti-atherothrombosis in human blood. In the latter case clot was treated with an oxidizer (H 2 O 2 ) and/or antioxidant (ascorbic acid) and/or fibrinolytic (SK: streptokinase) and/or MDA to understand the mode of action of MDA. In HL test, MDA concentration-dependently inhibited HL, where highest inhibition was found 67.87 ± 1.39% at the highest concentration (400 µg/mL) tested. In CL test, MDA was found to antagonize H 2 O 2 , while potentiated SK activity. However, the MDA + SK exerted effect was further reduced by the application of H 2 O 2 . Furthermore, MDA was found to protect the clot by H 2 O 2 -induced oxidizing effect. In conclusion, MDA may protect human erythrocytes from H 2 O 2 -induced damaging effects due to its antioxidative defense capacity, while thrombolytic activity via antioxidant-mediated pro-oxidative effect. The current protocol can be used in non-clinical thrombolytic drug screening.